Explore Our Science

We have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI), and Partnered Programs.

Our Portfolio

Molecular Targets

19

Clinical Compounds

24

Approved Products

8
Filter by:
Filters

MPNs and GVHD
Close
Open

Jakafi® (ruxolitinib)1

JAK1/JAK2

Myelofibrosis2, polycythemia vera2, GVHD2

status for mobile

ruxolitinib XR (QD)

JAK1/JAK2

Bioequivalence and stability testing

status for mobile

axatilimab3

CSF-1R

Chronic GVHD

status for mobile

zilurgisertib

ALK2

Myelofibrosis-associated anemia | 
± ruxolitinib

status for mobile

INCB57643

BET

Myelofibrosis | ± ruxolitinib

status for mobile

INCA33989

mutCALR

Myelofibrosis or ET with CALR mutation | ± ruxolitinib

status for mobile

INCB160058

JAK2-V617F

JAK2V617F-mutated myelofibrosis

status for mobile

General Hematology/Oncology
Close
Open

Pemazyre® (pemigatinib)

FGFR1/2/3

2L+ cholangiocarcinoma4, MLNs with FGFR1 rearrangement2,5

status for mobile

Monjuvi® (tafasitamab-cxix)   
Minjuvi® (tafasitamab)

CD19

r/r DLBCL2,6,7

status for mobile

Iclusig® (ponatinib)8

BCR-ABL

Chronic myeloid leukemia6
Ph+ ALL6

status for mobile

Zynyz® (retifanlimab-dlwr)9

PD-1 (mAb)

Merkel cell carcinoma2

status for mobile

pemigatinib

FGFR1/2/3

1L cholangiocarcinoma

status for mobile

pemigatinib

FGFR1/2/3

Glioblastoma

status for mobile

tafasitamab

CD19

1L DLBCL, r/r follicular lymphoma, 
r/r MZL

status for mobile

retifanlimab9

PD-1 (mAb)

Squamous cell anal carcinoma, NSCLC

status for mobile

retifanlimab9

PD-1 (mAb)

MSI-H endometrial cancer

status for mobile

itacitinib

JAK1

Cytokine release syndrome

status for mobile

INCB99280

PD-L1 (small molecule)

Cutaneous squamous cell carcinoma, solid tumors

status for mobile

INCB99318

PD-L1 (small molecule)

Solid tumors

status for mobile

INCAGN238510

LAG-3

Solid tumors

status for mobile

INCAGN239010

TIM-3

Solid tumors

status for mobile

INCA3245911

LAG-3×PD-1

Advanced malignancies

status for mobile

INCA3389011

TGFßR2×PD-1

Solid tumors

status for mobile

INCB123667

CDK2

Solid tumors

status for mobile

INCB161734

KRAS-G12D

KRASG12D-mutated solid tumors

status for mobile

Dermatology and Other IAI
Close
Open

Opzelura® (ruxolitinib) cream

JAK1/JAK2

AD2, vitiligo2,6

status for mobile

ruxolitinib cream

JAK1/JAK2

Pediatric AD, prurigo nodularis

status for mobile

ruxolitinib cream

JAK1/JAK2

Hidradenitis suppurativa, lichen planus, lichen sclerosus

status for mobile

povorcitinib

JAK1

Hidradenitis suppurativa, vitiligo

status for mobile

povorcitinib

JAK1

Prurigo nodularis, chronic spontaneous urticaria, asthma

status for mobile

zilurgisertib

ALK2

Fibrodysplasia ossificans progressiva

status for mobile

Partnered Programs
Close
Open

Olumiant® (baricitinib)12

JAK1/JAK2

Rheumatoid arthritis13, COVID-1913, AD5,6, alopecia areata2,5,6

status for mobile

Tabrecta® (capmatinib)14

MET

NSCLC with METex1413

status for mobile

capmatinib14

MET

Liver cancer

status for mobile

Updated as of February 13, 2024

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners. 

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax
4. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 5. Approved in Japan 6. Approved in Europe 7. Approved in Canada 8. European rights to Iclusig licensed from Takeda 9. Licensed from MacroGenics 10. Discovery collaboration with Agenus
11. Development in collaboration with Merus 12. Worldwide rights to baricitinib licensed to Lilly 13. Approved in multiple territories globally 
14. Worldwide rights to capmatinib licensed to Novartis

1L, first-line; 2L+, second-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; mAb, monoclonal antibody; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; mut, mutant; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.

Clinical Trials

At Incyte, we believe in the power of research to advance scientific innovation and improve patient health. Thanks to the ongoing dedication of the people who participate in our clinical trials, we strive to develop medicines that have the potential to make a meaningful difference in the treatment of disease.

Our Incyte Clinical Trials website provides information for patients and healthcare professionals, including the basics of how clinical trials work and details about clinical studies that Incyte is currently sponsoring across a number of therapeutic areas, including Oncology and Inflammation & Autoimmunity.

Clinical Trial Information for U.S. Patients

Clinical Trial Information for Healthcare Professionals

Are you a physician, researcher or institution representative interested in conducting external research?

Incyte supports significant independent research aimed at enhancing disease understanding and advancing the study of our products by generating health outcomes data and real-world evidence.

Proposals submitted to Incyte are reviewed by Incyte's scientific and medical committees, with approval based on scientific merit, patient-safety considerations, unmet medical needs, study design, availability of resources and feasibility of study conduct. If you’re interested in submitting a research proposal, please visit our online research portal.

For questions concerning Investigator Initiated Research conducted outside of the U.S., please contact Incyte at global_iir@incyte.com.

For questions concerning Investigator Initiated Research conducted in the U.S., please contact Incyte at us_iir@incyte.com.

 

Visit our company response page on COVID-19.

Filter by:
Filters